Thursday, October 22, 2026 Published by AdvancedCare USA Inc.

TheraNews
Subscribe

Archive summary Clinical & research

U.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation Status

Breakthrough Therapy Designation Based on Positive RECONNECT Phase 2 Clinical Data --

Summary of reporting by hastingstribune 1 min read Markdown

U.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation Status

Originally reported by hastingstribune. Read more

Source: https://www.hastingstribune.com/ap/business/u-s-fda-grants-reunion-neuroscience-s-luvesilocin-re104-breakthrough-therapy-designation-status/article_5b114c3c-802f-52d2-a194-d78b06cfa09e.html

Newsletter

The weekly digest

Weekly digest of US behavioral health policy and regulation, source-linked and practitioner-edited. Free; unsubscribe in one click.